France

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sanofi, Regeneron Begin Global Kevzara Clinical Trial Program In Patients With Severe Covid-19

Lead Product(s): Sarilumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 16, 2020

Details:

The US based trial will begin at medical centers in New York and will assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo.

Abivax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Abivax Doses First Patient in Phase 2b/3 COVID-19 Clinical Trial

Lead Product(s): 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine

Therapeutic Area: Infections and Infectious Diseases Product Name: ABX464

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 02, 2020

Details:

The randomized, double-blind, placebo-controlled miR-AGE study aims to measure the potential of ABX464 to limit viral replication as well as the severe inflammation that leads to acute respiratory distress syndrome (ARDS).

Biophytis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Biophytis Receives IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos for Treatment of COVID-19 Related Respiratory Failure

Lead Product(s): Sarconeos

Therapeutic Area: Infections and Infectious Diseases Product Name: BIO101

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: SGS Life Sciences

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2020

Details:

This pivotal, international clinical trial will be conducted in two parts, the first of which has the objective to assess treatment safety and provide an indication of activity of Sarconeos, in 50 hospitalized COVID-19 patients suffering from acute respiratory deficiency.

Biophytis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Biophytis Receives FDA IND Clearance for COVA Testing Sarconeos for the Treatment of Patients with COVID-19 Related Respiratory Failure

Lead Product(s): Sarconeos

Therapeutic Area: Infections and Infectious Diseases Product Name: BIO101

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2020

Details:

The COVA clinical program is designed to evaluate the efficacy and safety of Sarconeos (BIO101) as a treatment of the respiratory deterioration in COVID-19 patients with severe respiratory failure.

Abivax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Abivax Announces German Regulatory Approval of ABX464 Covid-19 Phase 2b/3 Clinical Trial

Lead Product(s): 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

The randomized, double-blind, placebo-controlled study is investigating early treatment (at diagnosis) in 1,034 COVID-19 elderly or high-risk patients (miR-AGE trial).

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Sanofi

Sanofi, Regeneron Begin Global Kevzara Clinical Trial Program In Patients With Severe Covid-19

Abivax

Abivax Doses First Patient in Phase 2b/3 COVID-19 Clinical Trial

Biophytis

Biophytis Receives IND Clearance for COVA, a Phase 2/3 Clinical Trial with Sarconeos for Treatment of COVID-19 Related Respiratory Failure

Biophytis

Biophytis Receives FDA IND Clearance for COVA Testing Sarconeos for the Treatment of Patients with COVID-19 Related Respiratory Failure

Abivax

Abivax Announces German Regulatory Approval of ABX464 Covid-19 Phase 2b/3 Clinical Trial